Other Personal Care Services (U.S., NAICS 81219) — A Rollup Investor Primer

1. Overview

NAICS (the North American Industry Classification System) code 81219, Other Personal Care Services, is a small federal container holding two industries that could hardly be less alike. One is Diet and Weight Reducing Centers (812191) — the non-medical, commercial diet-program business (WeightWatchers-style memberships, branded meal-and-coaching plans). The other is Other Personal Care Services (812199) — a sprawling catch-all of day spas, tanning salons, tattoo and piercing shops, waxing and lash studios, non-medical massage, and the like. Together they form a roughly $16.1 billion industry (2022 receipts) spread across about 34,300 payrolled locations employing 196,500 people, on top of a much larger base of solo operators the federal data don't count [1][2].

The real story of this level is the contrast between its two halves, and they are close to mirror images:

• 812199 is the mass — about 85% of receipts — and is one of the most fragmented industries in the entire economy: thousands of independent, cash-generative local service businesses, a few consolidating franchise and private-equity (PE) pockets, and no large public pure play [4].
• 812191 is the minority — about 15% of receipts — and is one of the most concentrated consumer-service industries, long ruled by a handful of national brands, now in a violent, drug-driven shakeout [3][6].

So the level is a barbell: a large, stable-to-growing, wildly fragmented services business bolted to a small, concentrated, structurally shrinking one. For investors, the two halves demand completely different playbooks — which is why this primer leads with how the children differ before treating the level as a whole.

2. What's inside — the two children and how they differ

The level splits cleanly into two industries with opposite structures, trajectories, and ownership. The contrast table is the heart of this primer:

Read the differences this way. 812199 supplies almost all of the level's revenue, locations, and jobs; if you look only at the headline totals, you are essentially looking at 812199. But 812199 is a bottom-up business — value is created one location and one recurring-membership customer at a time, and no single owner controls much of it. 812191 is the opposite: a top-down business where a few brands captured most of the money and are now being disintermediated by a category of medicines (GLP-1 drugs, discussed below) that didn't exist at scale five years ago. One half's central question is "who consolidates the fragments?"; the other's is "who survives the disruption?"

3. How big it is (the level's rollup — and the undercount)

The figures below are our ground-truth federal statistics for NAICS 81219, and they reconcile exactly as the sum of the two children — a useful integrity check. They measure the employer business base (locations and firms with payroll), not total consumer spending.

What the concentration tells you — and why the blend is misleading. The level's CR4 of 11.3% [2] sits between its two children (812191's ~63.5% and 812199's ~5.9%) [3][4], but it is not a meaningful "market": the four largest firms at this level are almost certainly the surviving national diet brands, whose combined revenue looks like a double-digit share of the combined $16 billion only because the diet half is so top-heavy. Averaged across a level that is 85% ultra-fragmented personal-care services, the 11.3% figure understates how concentrated the diet niche really is and overstates how concentrated everyday personal-care services are. The HHI is suppressed, so no single official measure of market power is published for the level [2]. Pay is low across both halves — roughly $30,900 per employee [1] — reflecting part-time counselors, estheticians, and hourly or commission-based service staff.

The undercount caveat is large here, and it runs two ways.

1. Nonemployer businesses are missing. Both CBP and the Economic Census size tables count only businesses with payroll [1][2]. The 812199 half in particular is dominated by sole proprietors and booth renters — solo tattoo artists, single-chair estheticians, mobile spray-tan and lash technicians — whom the Census tracks separately in its Nonemployer Statistics series, and in personal-care fields nonemployer counts typically run several times the employer count [18]. Industry trackers suggest on the order of 52,000 tattoo artists alone [17]. Treat $16.1 billion as the payrolled core, not total activity.

2. The adjacent "wellness/aesthetics" economy sits outside this code. Medical spas, injectables (Botox/fillers), laser hair removal, and physician-supervised or GLP-1-prescribing weight-loss clinics are classified as health care (offices of physicians / other health practitioners, NAICS 621xxx), not here [4][21]. The U.S. med-spa market alone is estimated near $7–8 billion, and the broader spending Americans do to lose weight — once drugs, surgery, and medical clinics are added — is valued near $135 billion [6][21]. This level captures the non-medical, non-hair, non-nail slice, and the fastest-growing money in both halves is migrating out of it into health-care codes.

For directional scale on the sub-segments (from private market-research firms using boundaries that don't match the federal code — read as indicative, not authoritative): U.S. spa revenue ~$22.5B across ~21,980 spas [15]; tanning ~$3.2B across ~15,500 salons [16]; tattoo studios and removal ~$4.5B [17]; and the legacy commercial-diet market's own external estimates well above its ~$2.4B federal receipts once digital and direct-selling adjacencies are counted [6].

4. Investable universe — where the value concentrates across the children

There is no large-cap or pure-play public stock for the level as a whole, and the two halves route to entirely different names. As a rule, no public company reports revenue on a clean NAICS basis, so public-company sales should never be read as level or industry market share.

Diet half (812191) — public turnarounds plus where the demand actually went. The remaining listed "pure plays" are turnaround situations, and the more direct exposure is to the telehealth firms and drug makers that captured the customer:

• WeightWatchers / WW International and Medifast (OPTAVIA) — restructuring diet brands mid-pivot toward GLP-1-integrated models [8][9]; Herbalife — broader direct-selling nutrition, only about half of it weight management [10].
• Adjacencies that captured the demand: telehealth (Hims & Hers, LifeMD) and the drug makers who are the clearest winners (Novo Nordisk, maker of Wegovy/Ozempic; Eli Lilly, maker of Zepbound/Mounjaro) [11][12][13].
• Private/PE owners: Kainos Capital's Wellful platform (Nutrisystem, and the relaunched Jenny Craig brand) [3]; plus thousands of independent, cash-pay medical weight-loss clinics — the fast-growing private frontier that sits outside the strict non-medical code.

Personal-care half (812199) — niche operators plus suppliers. The cleanest former public pure play, European Wax Center, was taken private by General Atlantic in a deal that closed in 2026 [14]. What remains public is small or diversified — XWELL (airport XpresSpa + Naples Wax Center) and OneSpaWorld (cruise-ship and resort spas) [19][20] — plus the "picks and shovels" suppliers (injectable, filler, and device makers such as AbbVie/Allergan, Galderma, Evolus, InMode, BeautyHealth, Cutera) that skew toward the medical aesthetics outside this code [21][22]. The operating scale actually lives in private hands: franchise chains (European Wax Center, Massage Envy, Hand & Stone, Palm Beach Tan, Sun Tan City) and PE aesthetics roll-ups (Milan Laser, LaserAway, SkinSpirit, Ideal Image) [14][22].

Bottom line for the level: value concentrates very differently in the two halves. In the diet half it sits in a few branded (and struggling) public companies and the drug/telehealth ecosystem around them. In the personal-care half it is spread across thousands of private units, with institutional value pooling in franchisors and PE platforms. There is no exchange-traded fund (ETF) for either the level or its children; public exposure comes only through the individual names or broad consumer-discretionary and health-care funds.

5. How the money works

Because the children have different unit economics, the level has no single business model. Owners in each half monetize differently:

• Diet half (812191): revenue is subscribers × price (the WeightWatchers subscription model, driven by retention, customer-acquisition cost vs. lifetime value, and heavy January seasonality); or product markup on branded meals and supplements (historically the real profit engine); or coach-distributor sales (Medifast's OPTAVIA, Herbalife), where the key metrics are active earning coaches and revenue per coach. The strategic pivot across survivors is identical — wrap a subscription or service fee around access to GLP-1 drugs, capturing the coaching-and-adherence layer rather than the molecule [8][9].
• Personal-care half (812199): revenue is capacity × utilization × ticket — how many treatment rooms, tanning beds, wax suites, or tattoo chairs, how full they run, and the average spend per visit — plus high-margin retail attach (lotions, skincare, aftercare) and, the real prize, recurring memberships (monthly wax passes, massage plans, unlimited-tanning). Membership revenue is exactly why franchised waxing, massage, and tanning consolidated while tattooing (built on the individual artist) did not. Franchising is asset-light: franchisors collect a royalty (commonly ~6% of a franchisee's sales) plus marketing and technology fees and grow by signing new units rather than spending capital.

What the two halves share: labor is the top cost (part-time counselors, licensed estheticians, therapists, artists — often commission-based or booth-rent), capacity is perishable (an empty room or unbooked hour is lost forever), and the durable value sits with brands that combine strong customer retention with disciplined site economics. Federal statistics provide none of the operating metrics investors actually track — retention/churn, comparable-center sales, average ticket, provider utilization, CAC payback, site-level EBITDA (earnings before interest, taxes, depreciation, and amortization), franchisee openings/closures — so those come from filings, Franchise Disclosure Documents, or private diligence.

6. Demand drivers

• Discretionary spending and the "self-care" normalization. Both halves are paid out of pocket and non-reimbursed, so demand tracks disposable income and consumer confidence — but grooming, wellness, and weight management have all shifted from luxury toward routine, a structural tailwind for the healthier sub-segments [15].
• Obesity prevalence (diet half). The Centers for Disease Control and Prevention (CDC) put adult obesity at 40.3% in its most recent measured national data — a long-run tailwind for anything labeled weight loss [7].
• The GLP-1 (glucagon-like peptide-1) drug shock (diet half — dominant force). Highly effective injectables deliver ~15–20% body-weight loss versus the low-single-digit results typical of behavioral programs. That efficacy gap reset consumer expectations and pulled spending toward drugs and prescribing clinics — simultaneously the diet half's biggest threat and, for players who integrate the drugs, its biggest opportunity (new demand for adherence, nutrition, and muscle-preservation services) [6].
• Aesthetics and social-media culture (personal-care half). Selfie/video culture and the mainstreaming of cosmetic enhancement drive tattoos, brows, lashes, waxing, and injectable-adjacent services; demographics split the demand (younger cohorts to tattoos/waxing/lashes, older/higher-income to spa/massage/anti-aging).
• Recurring formats. Membership and franchise models in both halves convert occasional splurges into scheduled, habitual spending — the mechanism behind most durable value creation here.
• Segment-specific headwind. Tanning is the clear exception — skin-cancer awareness, minor-use bans, and self-tanning alternatives are a secular drag on one of the larger personal-care sub-segments [24].

7. Regulation

Regulation is light and mostly state and local for the personal-care half, but the level's defining regulatory issue is a classification boundary: a business here must stay non-medical. The moment a diet center diagnoses, treats, or prescribes — or a spa performs injectables or laser treatment under clinical supervision — it moves into Health Care (Sector 62) with far heavier licensing, supervision, privacy, and advertising rules [3][4]. Beyond that boundary:

• Federal Trade Commission (FTC). Polices deceptive weight-loss advertising (claims must be backed by "competent and reliable scientific evidence") and auto-renewal / negative-option subscriptions — relevant to every membership model in both halves — and enforces the Franchise Rule, requiring a Franchise Disclosure Document (FDD) generally at least 14 days before a franchisee signs or pays [23][27].
• Food and Drug Administration (FDA). Regulates the dietary supplements and meal-replacement products the diet brands sell, the GLP-1 drugs they are racing to attach to (its rulings on drug shortages and compounding directly hit telehealth revenue) [28], and sunlamp products as medical devices for tanning [24].
• Indoor tanning is the most heavily regulated segment: 44 states plus D.C. restrict or ban minors' use, a proposed federal under-18 ban was withdrawn by the FDA in 2026 (leaving the state patchwork), and a 10% federal excise tax on tanning services still applies [24].
• Tattoo and piercing shops fall under state/county health-department licensing and the federal Occupational Safety and Health Administration (OSHA) Bloodborne Pathogens Standard because the procedures draw blood [25]. Spas, waxing, electrolysis, and esthetics generally require state cosmetology or esthetician licenses; massage and electrolysis are separately licensed in many states.

Notably, there is generally no licensure for a "diet counselor" (unlike registered dietitians) — a low barrier that historically let fad operators enter easily. The direction of travel across the level is more consumer-protection and health scrutiny, not less.

8. Consolidation

The two halves are consolidating for opposite reasons.

• Diet half — a distress-driven shakeout. Always concentrated (a few national brands), it turned an ordinary fad cycle into a structural collapse under GLP-1 pressure: Jenny Craig liquidated its ~500 centers (2023); WW International went through Chapter 11 (2025), cutting ~$1.15 billion of debt; Medifast's revenue roughly halved from its peak [3][8][9]. Consolidation here is convergence with medicine — behavioral brands buying into telehealth, telehealth natives attacking from the clinical side, and drug makers (Novo, Lilly) launching direct-to-patient channels that threaten to bypass everyone [11][12][13].
• Personal-care half — a roll-up runway. With a CR4 under 6% and a near-floor HHI, the default state is thousands of independents competing locally [4]. Franchising consolidated the repeat-visit, membership-friendly niches (waxing, massage, tanning), and private equity is the current force in the med-spa/aesthetics adjacency — industry trackers cite 50+ deals a year against a base still 90%+ independent (only ~3–4% PE-owned), a long runway [22]. European Wax Center's 2026 take-private fits the pattern of mature franchise systems moving off public markets [14].

What resists consolidation in both halves is the same: businesses whose value is an individual relationship rather than a brand or subscription — solo diet coaches with unsupported claims, and tattoo artists, boutique spas, and solo estheticians whose client book walks out the door.

9. Risks

• Substitution/disruption (diet half, existential). GLP-1 drugs directly replace the core value of a behavioral program; firms that don't integrate them face structural decline, and the drug economics cut both ways (cheaper drugs or oral pills could either crush programs further or expand the pool needing an adherence wrapper — genuinely uncertain) [6][28].
• Discretionary and cyclical (personal-care half). Spa visits, tattoos, and tanning are among the first cuts in a downturn; thin margins get squeezed by labor, rent, and (for tanning) energy costs.
• Labor supply and turnover (both). Dependence on licensed, often commission-based or booth-renting providers who can leave and take clients caps how much value accrues to the business versus the individual.
• Segment-specific secular decline. Tanning faces skin-cancer-driven bans and the excise tax [24].
• Regulatory and litigation exposure. Deceptive-claims and auto-renewal enforcement, franchise-disclosure obligations, health/sanitation violations, and — for anything touching drugs or medical treatment — telehealth, prescribing, and privacy rules [23][24][27][28].
• PE roll-up risk (personal-care half). Elevated aesthetics multiples plus leverage make returns depend on continued growth and multiple expansion — vulnerable if demand or exit markets soften [22].
• Financial/franchisee risk (both). WW's bankruptcy shows even a recognizable brand can carry crushing leverage; weak local operators, high rent, or closures reduce franchisor royalties and reach [8].
• Measurement risk. Federal figures understate solo/nonemployer activity, and public-company revenue bundles products, telehealth, international, and non-personal-care lines — never read it as level or industry market share [1][18].

10. How to invest, and the outlook

The level is not a single trade — pick a half. The two children need different playbooks.

Public routes (all indirect or niche). There is no large-cap or pure-play stock for the level. In the diet half, the choices are higher-risk turnarounds (WeightWatchers, Medifast; Herbalife for broader nutrition) or, more cleanly, the telehealth and drug makers who captured the demand (Hims & Hers, LifeMD; Novo Nordisk, Eli Lilly) — different business models, not interchangeable proxies [8][9][10][11][12][13]. In the personal-care half, the listed options are small or diversified (XWELL, OneSpaWorld) plus the aesthetics suppliers (AbbVie/Allergan, Galderma, Evolus, InMode, BeautyHealth, Cutera), most of which skew to the medical adjacency outside the code [19][20][21][22]. There is no dedicated ETF for either; check each name's segment revenue, retention, and balance sheet before treating it as exposure.

Private routes (where the operating scale lives).

• Diet half: franchise or open a branded center or a cash-pay weight-loss clinic ($300–$1,500/month per patient in the medical adjacency); back a telehealth/behavioral platform; or take buyout exposure via Nutrisystem's owner (Kainos/Wellful) [3][6].
• Personal-care half: own or franchise a membership-driven unit (waxing, massage, tanning, spa); buy an established independent (a $9M SBA size standard means nearly every operator is a small business, often SBA-financed); or back a med-spa/aesthetics roll-up [4][5][14][22].

Diligence in both halves rests on normalized location-level cash flow and the durability of repeat demand — separate service revenue from product, subscription, and any medical/drug revenue; examine cohort retention, CAC payback, site-level margins, franchisee cash returns, claims substantiation, licensing, and liquidity; and read the FDD independently for closures, litigation, and earnings claims [23].

Outlook (forward-looking judgment, not settled fact). The level's two halves are heading in opposite directions. The diet half is in structural decline as classically defined, even as the underlying demand to lose weight has never been larger — the winners will be operators that stop fighting GLP-1 drugs and wrap coaching, adherence, and maintenance services around them; the losers depend on one-off memberships or unsupported claims. The personal-care half is a fragmented, moderately growing services industry with selective consolidation — spa, waxing, massage, and aesthetics growing modestly ahead of the broader consumer while tanning slowly declines, and PE consolidation of aesthetics the dominant near-term catalyst. For the level overall, the sharper theme is that money is migrating out of the non-medical code entirely — into obesity drugs on one side and medical aesthetics on the other. The fragmentation, the diet-brand distress, and the roll-up pace are reported facts; the growth and multiple-durability calls are judgments.

---

Sources

1. U.S. Census Bureau, County Business Patterns: 2023, NAICS 81219 (establishments 34,344; employees 196,500; annual payroll $6.065B; Q1 payroll $1.470B; derived avg. pay ~$30,900). https://www.census.gov/programs-surveys/cbp.html
2. U.S. Census Bureau, 2022 Economic Census — Concentration of Largest Firms, NAICS 81219 (firms 28,073; receipts $16.063B; CR4 11.3%; CR8 14.9%; CR20 19.3%; CR50 23.1%; HHI suppressed). https://data.census.gov/table/ECNSIZE2022
3. Child primer — NAICS 812191 Diet & Weight Reducing Centers (federal figures: receipts ~$2.386B [2022 Economic Census], 2,481 establishments / 12,955 employees [2023 CBP], 1,376 firms, CR4 63.5%; Kainos/Wellful ownership of Nutrisystem and Jenny Craig). Consolidates 812191 primer sources 1, 2, 4, 6, 22, 23.
4. Child primer — NAICS 812199 Other Personal Care Services (federal figures: receipts $13.677B [2022 Economic Census], 31,863 establishments / 183,545 employees [2023 CBP], 26,697 firms, CR4 5.9%, HHI 13.4; scope and exclusions). Consolidates 812199 primer sources 1, 2, 3.
5. U.S. Small Business Administration, Table of Size Standards (NAICS 812191 = $27.5M; 812199 = $9.0M average annual receipts), 2023. https://www.sba.gov/document/support-table-size-standards
6. Marketdata Enterprises / GlobeNewswire, "U.S. Weight Loss Market Status & Forecast 2025–2026: GLP-1 Boom… $135 Billion Diet Market" (legacy commercial-programs segment est. −29% 2023, −24% 2024), 2026. https://www.globenewswire.com/news-release/2026/03/10/3253070/28124/en/
7. Centers for Disease Control and Prevention, "Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023" (adult obesity 40.3%), 2024. https://www.cdc.gov/nchs/products/databriefs/db508.htm
8. U.S. Securities and Exchange Commission, WW International 2025 Form 10-K (Chapter 11 reorganization, ~$1.15B debt cut, Nasdaq relisting). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000105319
9. U.S. Securities and Exchange Commission, Medifast (OPTAVIA) 2025 Form 10-K (product sales ~96% of revenue; coach-distributor model; LifeMD stake). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000910329
10. U.S. Securities and Exchange Commission, Herbalife Ltd. 2025 Form 10-K (weight management ~54.5% of sales). https://ir.herbalife.com/sec-filings
11. Fierce Healthcare / SEC, Hims & Hers Health (telehealth weight-loss line ~$725M, 2025; compounding-regulation exposure). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001773751
12. S&P Global Market Intelligence, Novo Nordisk (Wegovy/Ozempic; U.S. Wegovy sales ~$13B, 2025). https://www.spglobal.com/market-intelligence/en/
13. Axios, "Eli Lilly is the new king of weight-loss drugs" (Zepbound/Mounjaro), 2025. https://www.axios.com/2025/10/21/glp-1-brands-obesity-eli-lilly-weight-loss-drugs
14. U.S. Securities and Exchange Commission, European Wax Center, Inc. Form 8-K — completion of take-private by General Atlantic (closed May 8, 2026; $951M FY2024 system-wide sales; ~1,067 centers). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001856236
15. International Spa Association / Athletech News, 2024 U.S. Spa Industry Study ($22.5B revenue; ~21,980 spas; 187M visits — spans multiple NAICS codes). https://athletechnews.com/us-spa-industry-hits-record-breaking-revenue/
16. IBISWorld, Tanning Salons in the US — Market Size (~$3.2B; ~15,500 salons), 2025. https://www.ibisworld.com/united-states/market-size/tanning-salons/1721/
17. ResearchAndMarkets / IBISWorld, U.S. Tattoo Studios & Tattoo Removal Services Market Analysis 2024 (~$4.5B; ~11,600 studios; ~52,000 artists). https://www.businesswire.com/news/home/20240627329377/en/
18. U.S. Census Bureau, Nonemployer Statistics — FAQ (employer statistics exclude owner-only businesses; nonemployers reported separately). https://www.census.gov/programs-surveys/nonemployer-statistics/about/faq.html
19. U.S. Securities and Exchange Commission, XWELL, Inc. 2025 Form 10-K (XpresSpa airport spas; Naples Wax Center). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001410428
20. U.S. Securities and Exchange Commission, OneSpaWorld Holdings 2025 Form 10-K (cruise-ship and resort spas; 206 ships served). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001758488
21. Grand View Research / Precedence Research, U.S. Medical Spa Market Size (~$7–8B; med spas largely classified as health care, not 812199); U.S. Medical Weight Loss Clinics Market (cash-pay $300–$1,500/month), 2025. https://www.grandviewresearch.com/industry-analysis/medical-spa-market
22. CT Acquisitions / Physician Growth Partners, Med Spa & Medical Aesthetic M&A Trends (90%+ independent; ~3–4% PE-owned; 50+ deals/yr; LaserAway reported exploring >$2B sale at ~$150M EBITDA), 2026. https://ctacquisitions.com/guides/med-spa-ma-multiples-2026/
23. U.S. Federal Trade Commission, Franchise Rule (Franchise Disclosure Document; 14-day delivery requirement) and A Consumer's Guide to Buying a Franchise, 2007/2026. https://www.ftc.gov/legal-library/browse/rules/franchise-rule
24. U.S. Food and Drug Administration / Skin Cancer Foundation / Congress.gov, Sunlamps and Sunlamp Products (21 CFR 1040.20); indoor-tanning minor bans (44 states + D.C.); FDA withdrawal of proposed under-18 rule (Mar 2026); 10% ACA tanning excise tax, 2026. https://www.fda.gov/radiation-emitting-products/home-business-and-entertainment-products/sunlamps-and-sunlamp-products-tanning-bedsbooths
25. U.S. Occupational Safety and Health Administration, Bloodborne Pathogens Standard, 29 CFR 1910.1030 (tattoo/piercing occupational blood exposure), 1991. https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030/
26. U.S. Bureau of Labor Statistics, Occupational Outlook Handbook — Skincare Specialists (7%) and Massage Therapists (15%) projected employment growth, 2024–2034, 2025. https://www.bls.gov/ooh/personal-care-and-service/skincare-specialists.htm
27. U.S. Federal Trade Commission, Health Products Compliance Guidance (deceptive weight-loss advertising; substantiation standard), 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
28. U.S. Food and Drug Administration, "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize," 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize